Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Miltefosine - Endo International

Drug Profile

Miltefosine - Endo International

Alternative Names: D 18506; HePC; Hexadecylphosphocholine; HPC; Impavido; Miltefosin; Miltex

Latest Information Update: 15 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter Oncology; Zentaris
  • Developer AEterna Zentaris GmbH; Knight Therapeutics; MegaPharm Ltd; Profounda
  • Class Antineoplastics; Antiparasitics; Phospholipids; Quaternary ammonium compounds
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Candidiasis; Encephalitis; Acanthamoeba infections; Visceral leishmaniasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer metastases; Cutaneous leishmaniasis; Leishmaniasis; Visceral leishmaniasis
  • No development reported Acanthamoeba infections; Chagas disease
  • Discontinued Malignant melanoma

Most Recent Events

  • 08 Nov 2021 Miltefosine - Endo International receives Orphan Drug status for Candidiasis in USA
  • 28 Jan 2021 No recent reports of development identified for preclinical development in Acanthamoeba-infections in USA
  • 08 May 2019 Launched for Leishmaniasis (In adolescents, In adults) in Israel prior May 2019 (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top